Fate Therapeutics
FATE
157 hedge funds and large institutions have $88.9M invested in Fate Therapeutics in 2026 Q1 according to their latest regulatory filings, with 27 funds opening new positions, 55 increasing their positions, 33 reducing their positions, and 15 closing their positions.
80% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 15
67% more repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 33
51% more call options, than puts
Call options by funds: $124K | Put options by funds: $82K
25% more capital invested
Capital invested by funds: $71M → $88.9M (+$17.9M)
8% more funds holding
Funds holding: 146 → 157 (+11)
1.17% more ownership
Funds ownership: 62.56% → 63.73% (+1.2%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| 1 |
AQR Capital Management
Greenwich,
Connecticut
|
+$2.24M |
| 2 |
Two Sigma Investments
New York
|
+$2.11M |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$1.73M |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$1.45M |
| 5 |
ICM
Irenic Capital Management
New York
|
+$1.07M |
Top Sellers
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.81M |
| 2 |
VPC
Vestal Point Capital
New York
|
-$1.69M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
-$845K |
| 4 |
Millennium Management
New York
|
-$514K |
| 5 |
DMKJ
David M. Knott Jr
|
-$359K |
FATE Hedge Fund Activity: Q1 2026 in Review
157 of the 8,125 institutional investors tracked by Wall St. Rank reported a position in Fate Therapeutics (FATE) for Q1 2026, worth a combined $88.9M — up 25% from $71M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new FATE positions and 15 closed out — a net gain of 12 holders — while 55 added to existing stakes and 33 trimmed.
The largest buyer was AQR Capital Management, adding an estimated $2.24M. The largest seller was Point72 Asset Management, cutting an estimated $1.81M.
- 157 institutional investors held Fate Therapeutics (FATE) as of Q1 2026, up from 146 in Q4 2025.
- Funds reported $88.9M of Fate Therapeutics stock for Q1 2026, up 25% quarter-over-quarter.
- 27 funds opened new Fate Therapeutics positions in Q1 2026 and 15 closed out, a net change of +12 holders.
- The largest Fate Therapeutics buyer in Q1 2026 was AQR Capital Management, an estimated $2.24M added.
- The largest Fate Therapeutics seller in Q1 2026 was Point72 Asset Management, an estimated $1.81M sold.
Based on aggregated 13F filings for Q1 2026.